Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Improvement of type 2 diabetes in a lung cancer patient treated with Erlotinib.

× No keyword cloud information.

16 in total

1. Inhibition of Epidermal Growth Factor Receptor Activation Is Associated With Improved Diabetic Nephropathy and Insulin Resistance in Type 2 Diabetes.

Authors: Zhilian Li; Yan Li; Jessica M Overstreet; Sungjin Chung; Aolei Niu; Xiaofeng Fan; Suwan Wang; Yinqiu Wang; Ming-Zhi Zhang; Raymond C Harris
Journal: Diabetes Date: 2018-06-29 Impact factor: 9.461

2. Cancer, obesity, and diabetes: TKIs exert multiple effects on glucose homeostasis.

Authors: Minglin Lin; Junfei Jin
Journal: Nat Rev Clin Oncol Date: 2017-04-19 Impact factor: 66.675

3. Erlotinib and gefitinib, epidermal growth factor receptor kinase inhibitors, may treat non-cancer-related tumor necrosis factor-α mediated inflammatory diseases.

Authors: Marvin B Brooks
Journal: Oncologist Date: 2013

Review 4. Drug-induced hypoglycaemia: an update.

Authors: Chaker Ben Salem; Neila Fathallah; Houssem Hmouda; Kamel Bouraoui
Journal: Drug Saf Date: 2011-01-01 Impact factor: 5.606

5. Effects of Imatinib Mesylate (Gleevec) on human islet NF-kappaB activation and chemokine production in vitro.

Authors: Dariush Mokhtari; Tingting Li; Tao Lu; Nils Welsh
Journal: PLoS One Date: 2011-09-14 Impact factor: 3.240

6. Metformin and salinomycin as the best combination for the eradication of NSCLC monolayer cells and their alveospheres (cancer stem cells) irrespective of EGFR, KRAS, EML4/ALK and LKB1 status.

Authors: Zhiguang Xiao; Bianca Sperl; Axel Ullrich; Pjotr Knyazev
Journal: Oncotarget Date: 2014-12-30

7. Tyrosine kinase inhibitors of Ripk2 attenuate bacterial cell wall-mediated lipolysis, inflammation and dysglycemia.

Authors: Brittany M Duggan; Kevin P Foley; Brandyn D Henriksbo; Joseph F Cavallari; Akhilesh K Tamrakar; Jonathan D Schertzer
Journal: Sci Rep Date: 2017-05-08 Impact factor: 4.379

8. EGFR tyrosine kinase inhibitor (PD153035) improves glucose tolerance and insulin action in high-fat diet-fed mice.

Authors: Patricia O Prada; Eduardo R Ropelle; Rosa H Mourão; Claudio T de Souza; Jose R Pauli; Dennys E Cintra; André Schenka; Silvana A Rocco; Roberto Rittner; Kleber G Franchini; José Vassallo; Lício A Velloso; José B Carvalheira; Mario J A Saad
Journal: Diabetes Date: 2009-08-20 Impact factor: 9.461

9. Drug-Drug Interaction Potentials of Tyrosine Kinase Inhibitors via Inhibition of UDP-Glucuronosyltransferases.

Authors: Nan Zhang; Yong Liu; Hyunyoung Jeong
Journal: Sci Rep Date: 2015-12-08 Impact factor: 4.379

10. Novel EGFR inhibitors attenuate cardiac hypertrophy induced by angiotensin II.

Authors: Kesong Peng; Xinqiao Tian; Yuanyuan Qian; Melissa Skibba; Chunpeng Zou; Zhiguo Liu; Jingying Wang; Zheng Xu; Xiaokun Li; Guang Liang
Journal: J Cell Mol Med Date: 2016-01-14 Impact factor: 5.310